The evidence is insufficient for safe use of elderly donors in adult-to-adult living donor liver transplantation (LDLT). The aim of this study was to evaluate the outcomes of right lobe LDLT by donor age (55 versus < 55 years). All living donors who underwent right hepatectomy at the authors' institution between March 2008 and December 2015 were divided into 2 groups: group A with an age 55 years and group B with an age of <55 years. The selection criteria for elderly donor were preservation of middle hepatic vein, remnant liver volume 30%, and no or mild fatty liver. The matching criteria of recipients for the elderly donor grafts were Model for End-Stage Liver Disease score of <25, graft-to-recipient weight ratio of >0.8%, and body mass index of <25 kg/m 2 . Perioperative data, complications by the Clavien classification, and the outcomes with at least 12 months follow-up were compared. A total of 42 donors were enrolled in group A and 498 in group B. No significant differences in operative parameters were observed between the 2 groups. The peak postoperative aspartate aminotransferase, alanine aminotransferase, and total bilirubin levels made no difference between the 2 groups. The peak international normalized ratio level was significantly lower in group A than in group B (P 5 0.001). All donors recovered completely with no significant differences in overall complications between the 2 groups. All recipients of grafts from donors in group A showed good initial function with no significant differences in 1-year graft and patient survival or biliary complications between 2 groups. These results provide clinical evidence for feasibility of right hepatectomy in living donors aged 55 years without compromising donor safety or recipient outcomes.
With the profound organ shortage resulting in longer waiting times and increased mortality for those awaiting liver transplantation, many efforts have been made to expand the living donor pools to increase the applicability of living donor liver transplantation (LDLT) in patients who have no other choice. Selective use of living donors with liver remnants <30%, (1) intra-abdominal adhesion, (2) previous abdominal surgery, (3) select utilization of obese donors, (4) and strategies employing ABOincompatible grafts (5) have been proposed specifically for LDLT.
Another issue that modern transplantation surgery has to cope with, in order to keep abreast of the progressive increase in the mean life expectancy of the general population, may be the use of elderly living donors. Compared with older adults, younger ones are preferably considered for living donor candidates for LDLT due to concerns about possible increased morbidity in older donors and poorer graft outcomes in recipients. Several studies reported the use of elderly living donors. (6) (7) (8) (9) (10) (11) However, they recruited a relatively small number of donors with different age cutoffs, focused mainly on the graft and recipient survivals, or only included donors aged 60 years or younger, which gave conflicting results and was not enough to draw a clear conclusion on the feasibility and safety of right hepatectomy in elderly donors.
The evidence is insufficient in defining a safe upper age cutoff based on preoperative evaluation in living donors undergoing right hepatectomy in LDLT. There should be no compromise on donor safety, but in the current era of robustly accumulated experience in LDLT and recent improvements in surgical technique and management, safe use of elderly donors for LDLT using the right liver can be compatible with the continuing efforts to expand the donor pool.
The goals of this study were as follows: to evaluate the outcomes of living donors aged 55 years old or older after right hepatectomy by the selection criteria: preservation of middle hepatic vein (MHV), a remnant liver volume more than 30%, and no or mild fatty change in good health, in comparison with those of all donors younger than 55 years in the same study period, and to compare graft and patient survival in the recipients of grafts from both the 2 donor groups.
Patients and Methods

STUDY DESIGN
All living donors who underwent right hepatectomy at the National Cancer Center, Korea between March 2008 and December 2015 were considered for this retrospective study, and the institutional review board approved the study. Donor characteristics, operative outcomes, and postoperative complications were reviewed from a prospectively maintained database. To assess the outcomes of living donors aged 55 years or older, the donors were divided into 2 groups: group A with an age 55 years and group B with an age of <55 years, and the 2 groups were then compared. The matching criteria of recipients for the elderly donor grafts were Model for End-Stage Liver Disease score of <25, graft-to-recipient weight ratio of >0.8%, and body mass index of <25 kg/m 2 . The primary endpoint was donor complications stratified by grade according to the Clavien classification. (12) The secondary endpoints include operative outcomes (operative time, blood loss, transfusion requirement, macrovesicular steatosis on pathology, actual graft weight, mean daily drain amount, and postoperative hospital stay) and postoperative peak serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin (TB), and international normalized ratio (INR). Postoperative liver failure was defined as prothrombin time (PT) < 50% and TB > 50 mmol/L on postoperative day (POD) 5 (the 50-50 criteria). (13) In recipients, the INR and TB levels on POD 7 were checked to determine early graft function. The recipient 1-year survival rate, the 30-day mortality rate, and the incidence of biliary complications were compared between the 2 groups.
DONOR SELECTION AND EVALUATION
Our LDLT program started with the upper age limit of 59 years in January 2005, but initially living liver donors had included an age between 16 and 51 years. (14) Then, after the learning curve was overcome over more than 3 years, elderly donors have been selectively accepted since March 2008.
The donor selection criteria and evaluation have been described elsewhere. (14) Briefly, all living donors volunteered and signed the informed consent about the items deliberated by the Ethics Group of the Vancouver Forum, (15) and all LDLTs were approved by the Korean Network for Organ Sharing after full medical and psychiatric assessment by health care professionals.
Imaging evaluation included Doppler ultrasonography (US), computed tomography (CT) with volumetry, and intraoperative cholangiography or magnetic resonance cholangiography. Triphasic CT was performed to delineate vascular anatomy, to assess removal of the MHV, and to calculate the volumes of the whole liver, the right liver, and the remaining left liver, where volume determination was performed by tracing the right liver graft and the whole liver on 3-mm CT slices, and the enclosed area was calculated and integrated.
Steatosis in each donor was graded as none (normal US liver structure), mild (slight increase of echogenicity, normal visualization), moderate (diffuse increase of echogenicity, slight impaired visualization), or severe (marked increase of echogenicity, poor or no visualization) on the basis of increasing echogenicity of the liver parenchyma compared with that of the right kidney and decreased visualization of the diaphragm and intrahepatic vessel borders. (16) Preoperative liver biopsy was performed selectively in donors with a significant history of alcohol intake, body mass index of >30 kg/m 2 , abnormal liver enzyme abnormalities, or a moderate degree of steatosis on imaging studies. Steatosis was assessed as the percentage of hepatocytes in the microscopic field containing a lipid vacuole larger than the diameter of the nucleus and displacing the nucleus. The percentage of macrovesicular steatosis was classified into 5 categories (<5%, 5%-10%, 11%-20%, 21%-30%, and >30%). Donors with mild hepatic steatosis were considered acceptable candidates for living donation according to the percentage of steatosis graded as none (<5%), mild (5%-33%), moderate (>33%-66%), and severe (>66%). (17) Upper and lower endoscopy examinations were routinely done to donor candidates who were older than 40 and 50 years, respectively, or who had any gastrointestinal symptom. No potential donor with any concomitant abnormal medical or psychological condition was allowed to undergo the donor operation. Furthermore, smoking or taking oral contraceptives was prohibited in all donor candidates within 6 weeks before surgery in order to reduce the risk of venous thromboembolic disease.
In principle, a remnant liver volume 30% by CT volumetry was chosen as the preferred minimum cutoff. However, if donors were <50 years old and in good physical and psychological health without more than mild fatty liver or any medical disorder including laboratory abnormality, a remnant liver volume <30% was selected carefully with the MHV absolutely preserved in donors.
(1)
SURGICAL PROCEDURE
The technical evolution and refinements over the study period on living donor right hepatectomy have been specified previously. (18) (19) (20) (21) (22) The current surgical technique is as follows.
An upper midline incision above umbilicus is used, and a wound protector is installed. After the right liver is mobilized with the sizable inferior right hepatic veins saved, if present, the right Glisson's pedicle is dissected following cholecystectomy and transection of the inferior parenchyma of caudate lobe up to the hepatic hilum. A tape is located along the inferior vena cava with its upper end between right hepatic veins and MHVs and with its lower end between the right and left Glisson's pedicles on the left side of the saved inferior right hepatic vein, if existent. Parenchymal transection is performed along the right side of the main trunk of MHV with a hanging maneuver employed consistently from the start of liver parenchymal transection until the tape is exposed. Any MHV branch over 5 mm in diameter is saved for reconstruction. After complete parenchymal transection, heparin (5 IU/kg) was given intravenously and then the right Glisson's pedicle is dissected into the right hepatic artery, portal vein, and hepatic duct. With no operative cholangiography, the right hepatic duct is ligated just at the right side of the confluence under a clear view, and the left side of the ligature was cut. The right hepatic artery, portal vein, and hepatic vein are divided at each bifurcation without narrowing the remnant stumps in time for the recipient operation. The graft is moved to a basin containing histidine-tryptophanketoglutarate solution. Then, the falciform ligament is reconstructed to maintain the remnant left liver in the original anatomic position, ensuring the remnant liver is well perfused, and a drain is placed in the right liver fossa.
POSTOPERATIVE CARE AND FOLLOW-UP
All donors were extubated before leaving the operating room. Prophylaxis for thromboembolism with early mobilization and compressive stockings was started on the day before the operation and continued until discharge, but low-molecular-weight heparin was used in donors over the age of 60 years for 1 week postoperatively. Intravenous patient-controlled analgesia was applied for 3 days after surgery. Early feeding and early ambulation no later than 2 days after the operation were encouraged. Routine laboratory tests were checked daily for the 3 consecutive PODs, and then every other day during the hospital stay. Follow-up CT was routinely checked at 1 week, 1 month, and 1 year after operation. After discharge, all donors were followed with routine laboratory tests at 1 month after surgery, then 3 months later, and thereafter every 6 months.
STATISTICAL ANALYSIS
Categorical and continuous variables were compared using the Fisher's exact test and the Mann-Whitney U test, respectively. A P value < 0.05 was considered statistically significant. All analyses were performed using the SPSS 22.0 statistical software package (IBM, Inc., Chicago, IL).
Results
DONOR CHARACTERISTICS
During the study period, of 58 donor candidates with an age of 55 years screened, 16 (27.6%) were rejected. The reasons for donor disqualification included a remnant liver volume < 30% in 2 candidates, moderate or severe fatty change liver in 6 candidates, and underlying diseases in 8 candidates.
A total of 540 donors who underwent right hepatectomy were enrolled with 42 in group A and 498 in group B. The donor ages ranged from 16 to 76 years. Twelve donors were aged 60 years or older. Donor characteristics are listed in Table 1 . Only age had a significant difference between the 2 groups (P < 0.001). There were no significant differences in sex, body mass index, calculated donation liver volume, remnant-tototal liver volume ratio, and fatty change on US between the 2 groups.
OPERATIVE OUTCOMES
There were no significant differences between the 2 groups in terms of operative parameters (Table 2) .
MORBIDITY AND MORTALITY
The postoperative peak serum AST, ALT, and TB levels made no difference between the 2 groups ( Table  3 ). The median peak serum INR level was lower in group A than in group B (1.48 versus 1.79; P 5 0.001). The liver enzyme elevation and hyperbilirubinemia in the immediate postoperative period declined smoothly over a week in all donors (data not shown). No donors developed postoperative liver failure as previously defined.
The median duration of postoperative follow-up was 51.4 months (range, 12.1-106.3 months) in group A and 58.3 months (range, 12.3-107.3 months) in group B. All donors recovered completely and returned to their previous activities with no significant difference in overall complications between the 2 groups (Table 4) .
RECIPIENT CHARACTERISTICS AND OUTCOMES
ABO-incompatible LDLT was significantly more common in group A than in group B (23.8% versus 9.6%; P 5 0.004). Otherwise, the age, sex, body mass index, Model for End-Stage Liver Disease score at the time of LDLT, graft-to-recipient weight ratio, total ischemic time, and POD 7 INR and TB levels were not significantly different between the recipients of the 2 study groups. There were also no significant differences both in the 30-day mortality rate and 1-year survival rate between the 2 recipient groups. During the median follow-up period of 54.2 months (range, 12.5-105.9 months), the incidence of biliary complications in recipients of the 2 donor groups did not reach statistical significance (Table 5) .
Discussion
A major concern in LDLT using the right liver from elderly living donors is regarding the potential of agerelated morbidity, and a recent report showed that donor age > 50 years was associated with a higher risk of major complications.
(23) Therefore, exploring the upper limit of age in living liver donors may be an ethical challenge. However, the outcome after living donor hepatectomy is due not only to age, but also to the other factors of the donor at the time of surgery such as remnant liver volume size, fatty change, undetected NOTE: Data are given as median (range) or n (%), unless otherwise noted. NOTE: Data are given as median (range) or n (%).
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underlying illness, and so on. Moreover, a second complication such as bile leak, infection, or accidental over-anticoagulation can potentially contribute to a cycle of fatal complications. The present analysis was performed to determine if an age of >55 years should be viewed as a relative or absolute contraindication to living donor right hepatectomy. With a median follow-up time of 57.8 months, the overall donor complication rate was 6.5%, with no significant difference between older and younger donors. Actually, the only significant difference in outcomes was made in the peak serum INR level, which was lower in group A than in group B. The peak serum TB level was also lower in group A than in group B, though it did not reach statistical significance. These are new and interesting findings that could be explored in future studies with even higher resolution and more statistical power to confirm such differences. One possible explanation for the better outcomes of the 2 postoperative parameters may be a higher metabolic demand in the younger than in the older, suggesting that old age per se might contribute to the safety in terms of liver function after right hepatectomy. In all donors, the serum AST, ALT, TB, and INR levels were normalized within 1 month.
Allograft function, morbidity including biliary complications, and graft survival rates were not significantly different between the two recipient groups of older and younger grafts. These observations are compatible with the claim that LDLT from older donors may be permitted without adversely affecting donor safety or recipient outcomes. However, careful matching of donors and recipients is mandatory especially in using the liver grafts from elderly donors because many donor and recipient factors impact graft survival after LDLT. In this study, considering the potential agerelated risks, the elderly liver grafts were matched to the recipients with Model for End-Stage Liver Disease score of <25, graft-to-recipient weight ratio of >0.8%, and body mass index of <25 kg/m 2 . The liver grafts from elderly donors were avoided in recipients with liver disease due to hepatitis C virus because they are particularly associated with poorer outcomes. (24, 25) Otherwise, there were no limits in terms of recipient age, sex, or ABO incompatibility. Further studies are warranted to investigate more specific indications about the use of older donors.
In this study, all recipients in group A had no other potential donors but the older ones. Notwithstanding, an age of 55 years was strictly restricted to those donors who meet the following criteria: preservation of MHV, remnant-to-total liver volume ratio 30%, and no or mild fatty change in healthy condition. A total of 42 (7.8%) donors met the criteria with the oldest being 76 years old. The 76-year-old female donated the right lobe of her liver to her 75-year-old husband. (26) The couple made uneventful recoveries and were discharged on POD 7 and 10, respectively. The couple has had no complication so far and is currently in good health with normal liver function 59 months after surgery.
The important potential limitation to this study includes the possibility of a type II error due to a relatively small sample size of group A compared with group B, which might be related to no statistically significant difference in overall outcomes between the study and control groups. And those over 55 years old were compared with the entire population of donors under 55 years old creating too wide an age range of controls (aged 16-55 years) to generate meaningful inferences. It must be remembered that the older donors over 55 years old in the study group represent a highly selected group, which likely does not represent the unscreened donor population presenting at any given center. Therefore, these results should not be interpreted as implying that all prospective donors over the age of 55 years old will have excellent outcomes.
However, this study represents the entire donor population in a single institution that excluded those during the early learning period, in which consistency was maintained by a professional group in performing clinical practice including donor selection, surgical procedure, and postoperative care as well as longterm follow-up, yielding a low overall complication rate of 6.5% and, to our best knowledge, is the first study that demonstrated the safety and feasibility of right hepatectomy in living donors aged 55-76 years old. Previous reports have defined "older donors" as those over 44 or 50 years, (7, 9, 10) thereby diluting any contribution from those aged 55 years old.
Last but not least, LDLT using right lobe from a living donor older than 55 years appeared to be a reasonably safe procedure for both the donor and recipient and the age per se is certainly not a contraindication to living donor right hepatectomy. This study provides clinical evidence that living donors with an age of 55 years or older deserve consideration for right hepatectomy under the above-mentioned 3 conditions when no other donor is available in the present era with accumulated experience and improved surgical technique and management. 
